Regen BioPharma Inc (RGBP)

[cvinvestor]

Yes, we know from PRs that dCellVax needed further studies because, like HemaXellerate, the data submitted with IND was not under qualified lab protocol. That is why they contracted with Dr. Kesari to perform the experiments again and it was stated that the IND would most likely be modified. Why, we don't know since the company lacks transparency and full disclosure on these issues.

The response and new IND was supposed to be file in Q2, so while late, at least it is getting done and since Dr. Kesari oversaw the experiments and revised IND I suppose as well, at least there is a good chance of meeting FDA approval within Q4 which would then give RGBP 2 approved pipeline products ready for human clinical trials. One for aplastic anemia and one for breast cancer. That should have some value.

If indeed they file for expansion of HemaXellerate and get approval in Q4, I would hope price would at least double from current levels, but as we've discussed in past, that depends on funding and whether we see further dilution at .03/share.